Led · Equity · May 2026

Sylvarum develops and deploys non-thermal (cold) plasma seed treatments that aim to improve germination, reduce pathogens, and revitalize seeds without chemical residues. Their technology has been validated in trials reporting a 60% reduction in seed latency, an active treatment window of six to eight months, and estimated savings of about US$800,000 per processing plant, with broader industry citations of roughly 10% production recovery. The core team and technology trace to academic research led by Dr. Karina Balestrasse (FAUBA/CONICET) and Dr. Leandro Prevosto with over 15 years of research experience. Sylvarum’s business model sells the treatment as an integrated service to seed companies rather than as standalone equipment, creating recurring revenue potential and lower adoption barriers. Financially, the company recently raised US$850,000 from national and international investment funds, including Inventure and the Aapresid fund. The company positions itself against conventional chemical treatments and other physical seed-conditioning methods by emphasizing a science-backed, chemical-free process that integrates into existing processing plants.

Participated · Equity · May 2026

Algorithmiq develops end-to-end quantum-classical computing frameworks to simulate complex therapeutics and accelerate drug discovery. The company demonstrated a workflow running on IBM hardware using up to 100 qubits to simulate the activation pathway of a photosensitizer drug currently in Phase II trials. Algorithmiq presented a framework that meets requirements for current-hardware viability, biological relevance, and comparability with modern classical methods. It has partnerships and contributions with Microsoft and IBM, and participated in projects such as the Quantum Advantage Tracker. The company has operations in Italy, Finland, the U.K., Ireland, and the U.S. Dr. Sabrina Maniscalco is CEO and a co-founder.

Participated · Series C · Feb 2026

Stockholm-based Lassie combines insurance expertise with engineering automation to create a pet insurance product that emphasizes preventive care. Through its mobile app, the company supplies educational content, activity-based rewards, and localized insurance policies, encouraging owners to keep pets healthy while reducing future claims. AI supports rapid, end-to-end claims processing—German customers, for example, can photograph a vet bill and receive reimbursement for simple treatments within minutes. Lassie is also building an ecosystem around pet wellness, partnering with Lidl to embed insurance in the Lidl Plus rewards program and with Tractive to link GPS-tracked activity data to incentives. Fresh capital will fund additional AI development, deeper automation, and entry into more of Europe’s major pet-insurance markets. The company’s prevention-centric model seeks to lower costs for both owners and insurers while capturing a growing share of Europe’s expanding pet-care spend.

Participated · Series A · Feb 2026

Capalo AI, founded in 2022, develops an AI-powered platform that aggregates and orchestrates large-scale battery assets and renewable generation into a single virtual power plant. By combining high-quality forecasting data with proprietary AI models, the software continuously optimises battery operation and executes real-time trades across electricity markets. This approach helps mitigate grid volatility caused by increasing wind and solar penetration and rising power demand from data centres and electric vehicles. The company currently operates in Finland, Sweden, Latvia, and Lithuania, where it maximises the value of both stand-alone and co-located storage assets. Management plans to expand into additional European markets by 2026 while growing its customer base. With fresh Series A capital, Capalo AI will scale its optimisation and trading capabilities, aiming to accelerate the deployment of intelligently managed battery storage across Europe. No operating metrics such as revenue or installed capacity were disclosed in the article.

Participated · Seed · Jan 2026

Avenue Biosciences has built what it says is the first platform capable of measuring and modulating the cellular secretory pathway at scale, coupling massively parallel wet-lab screening of 5,000–6,000 signal peptide variants with machine-learning models. By identifying optimal peptide “addresses” in a single experiment, the technology can rescue stalled projects and shave years off traditional, sequential trial-and-error workflows. Originating from years of research at the University of Helsinki, the platform already serves contract development and manufacturing organizations (CDMOs) and pharmaceutical companies, and the firm generated revenue in its first year after emerging from stealth at the end of 2024. Investors see the approach as a route to lowering costs and unlocking complex biologics that have previously failed due to poor expression yields. The company combines experimental data with computational insights, continually refining prediction tools as scientific understanding deepens. With total capital raised now at $8.7 million, Avenue plans to channel fresh funds into expanding its team of wet-lab scientists and strengthening its scientific capabilities before broader commercial scale-up.